echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Quit smoking, alcohol, gambling, one medicine can quit addiction?

    Quit smoking, alcohol, gambling, one medicine can quit addiction?

    • Last Update: 2020-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    U.Sresearchers released a report on the 9th, pharmaceutical giant Pfizer Incdeveloped a smoking cessation drug can be used to eliminate alcohol addiction, and perhaps even to eliminate gambling and other addictive behaviors, called "one-purpose addiction drugs."But some researchers disagreeWhat is the "potential" of this smoking cessation drug, called Varenicline? The medical profession has not yet reached a conclusion" Universal addiction??Varenicline, developed by Pfizer inc., was listed in the U.Slast August as a smoking cessation drug and is registered under the trademark "Chantix."Preliminary studies have shown that Varenicline can quit not only, but also alcohol, U.Sscientists said in a report published MondayThe researchers further suggest that Varenicline may also be able to get rid of addictions such as gambling and painkiller dependence" The most surprising thing is that, in addition to helping people quit safely, it is a potential drug to fight alcohol dependence," said Celena Bartlett, a neurologist at the University of California, Ernest Gallo Clinical Research CenterBartlett was one of the people who led the studyAt the same time, some scientists have questioned the results of The Bartlett team's findingsThey believe that there is no so-called "one-stop drug" in the worldThe scientists say Varenicline is more directly effective in treating Alzheimer's and Parkinson's disease than it is about addiction" Scientific studies the "rat withdrawal" show that nicotine in tobacco is sucked into the body and binds to specific receptors in the human brain, prompting the happy central centers of the brain to release dopamine, producing a "reward effect." Varenicline's principle of quitting smoking is that its drug ingredients can shut down nicotine-binding receptors in the human brain, thereby reducing the pleasure that the brain produces when smoking The study found that alcohol and nicotine act on the same areas of the brain, so Varenicline, which can be used to quit smoking, should also apply to alcohol cessation The University of California and the U.S Institute of Alcoholism and Alcoholism tested Varenicline's alcohol-related effectiveness The researchers trained a group of "greedy cup" mice and then let them take Varenicline The results showed that Varenicline was effective in restricting the "cup-goff" behavior of mice, and when they stopped taking the drug, the mice stopped drinking again, but no longer "drinking." On this basis, the researchers are planning human experiments "Varenicline is a drug for humans," said Mark Egley, an expert at the American Institute of Alcoholism and Alcoholism Although a series of studies on animals have shown a good effect on alcohol withdrawal, it is not clear what effect it will have on humans "
    apply for an expanded use
    so-called "no family of tobacco and alcohol", smoking and drinking often go hand in hand Christopher DeFiber, an associate professor of pharmacology and neurology at the University of North Texas, says it's not surprising that a drug has both smoking cessation and alcohol ism Alan Collins, an expert at the University of Colorado, says using smoking cessation drugs to treat alcohol addiction is an "obviously good way." But he also pointed out that Varenicline's effects on quitting and drinking vary from person to person, and that it cannot be expected to help all smokers and drinkers overcome their addiction The U.S Food and Drug Administration (FDA) has previously approved Varenicline for sale as a smoking cessation drug Pfizer is now considering whether to apply to the FDA for an expansion of drug use "Until you get a lot of data on the drug's new features, it's hard to say whether an application can be approved and it's going to wait and see," said Stephen Ledler, a Pfizer spokesman " (Wu Sijia)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.